Adrafinil

Adrafinil (CRL-40028, Olmifon) is a synthetic diphenylmethyl sulfinyl hydroxamic acid compound and the first clinically introduced member of the eugeroic (wakefulness-promoting) pharmacological class, marketed in France from 1986 to 2011 for the treatment of inattention, drowsiness, and vigilance deficits in elderly patients. The compound functions as a prodrug: hepatic metabolism converts adrafinil to its primary active metabolite modafinil (CRL-40476, 2-diphenylmethylsulfinylacetamide), which was subsequently developed independently and received regulatory approval in the United States (1998), the European Union, and more than 20 additional jurisdictions for the treatment of narcolepsy, obstructive sleep apnea-associated excessive daytime sleepiness, and shift work sleep disorder. The prodrug conversion proceeds through enzymatic hydrolysis of the terminal hydroxamic acid to yield modafinil, with concurrent production of the inactive metabolite modafinilic acid (CRL-40467). The pharmacological activity of adrafinil is therefore substantially attributable to modafinil, an atypical dopamine reuptake inhibitor that binds the dopamine transporter (DAT) with low micromolar affinity (Ki approximately 2.3 micromolar) and produces wake-promoting effects through a cascade involving elevated extracellular dopamine, activation of D1 and D2 dopamine receptors, downstream stimulation of lateral hypothalamic orexin (hypocretin) neurons, secondary activation of tuberomammillary histaminergic projections, and modulation of cortical glutamatergic and GABAergic tone. Positron emission tomography studies in humans have demonstrated that modafinil at clinical doses occupies approximately 50 to 57 percent of striatal dopamine transporters, an occupancy level comparable to methylphenidate, though modafinil produces substantially less reinforcing subjective effects and lower abuse liability than classical psychostimulants. Clinical evidence for adrafinil itself is confined to six principal studies conducted in France between 1979 and the mid-1990s, predominantly in ambulatory and hospitalized elderly patients (aged 45 years and older, majority older than 65 years) exhibiting vigilance, attention, memory, and affective complaints. These studies reported improvements in attention, wakefulness, self-evaluated vigilance, depressive symptom scores, and functional autonomy, though the trial designs, outcome measures, and sample sizes did not meet the evidentiary standards that would later govern modafinil registration. The compound was voluntarily withdrawn from the French market in September 2011 following a regulatory review by the Commission d’Autorisation de Mise sur le Marche that concluded the clinical evidence was insufficient to establish benefit and that the known adverse effect profile, including hepatic enzyme elevations with chronic use and rare skin reactions, constituted an unfavorable risk-benefit ratio given the availability of modafinil as a more potent, better characterized, and directly acting alternative. Adrafinil is not a controlled substance in the United States, the United Kingdom, Canada, or most other jurisdictions, and is sold as an unregulated research compound and dietary supplement. This monograph reviews the chemistry, synthesis, and stereochemistry of adrafinil; the prodrug conversion and the molecular pharmacology of its active metabolite modafinil; the pharmacokinetic profile including hepatic biotransformation; the preclinical pharmacology in rodent, feline, and primate models; the clinical evidence base across vigilance, narcolepsy, and cognitive endpoints; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal including hepatotoxicity; and a structured comparative assessment of five wakefulness-promoting alternatives against adrafinil on five competency standards.